ST Pharm Co Ltd
KOSDAQ:237690
Intrinsic Value
ST Pharm Co., Ltd. develops and manufactures pharmaceutical products. [ Read More ]
The intrinsic value of one ST Pharm Co Ltd stock under the Base Case scenario is 129 191.06 KRW. Compared to the current market price of 91 200 KRW, ST Pharm Co Ltd is Undervalued by 29%.
Valuation Backtest
ST Pharm Co Ltd
Run backtest to discover the historical profit from buying and selling ST Pharm Co Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
ST Pharm Co Ltd
Current Assets | 348.4B |
Cash & Short-Term Investments | 90.1B |
Receivables | 122.6B |
Other Current Assets | 135.7B |
Non-Current Assets | 327.1B |
Long-Term Investments | 17.7B |
PP&E | 280.1B |
Intangibles | 13.5B |
Other Non-Current Assets | 15.7B |
Current Liabilities | 83.7B |
Accounts Payable | 17.7B |
Accrued Liabilities | 8.3B |
Short-Term Debt | 20.9B |
Other Current Liabilities | 36.9B |
Non-Current Liabilities | 207.1B |
Long-Term Debt | 161.8B |
Other Non-Current Liabilities | 45.3B |
Earnings Waterfall
ST Pharm Co Ltd
Revenue
|
285B
KRW
|
Cost of Revenue
|
-172.9B
KRW
|
Gross Profit
|
112.1B
KRW
|
Operating Expenses
|
-78.6B
KRW
|
Operating Income
|
33.5B
KRW
|
Other Expenses
|
-13.9B
KRW
|
Net Income
|
19.6B
KRW
|
Free Cash Flow Analysis
ST Pharm Co Ltd
Profitability Score
Profitability Due Diligence
ST Pharm Co Ltd's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
Score
ST Pharm Co Ltd's profitability score is 47/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
ST Pharm Co Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
ST Pharm Co Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
ST Pharm Co Ltd
According to Wall Street analysts, the average 1-year price target for ST Pharm Co Ltd is 110 415 KRW with a low forecast of 96 960 KRW and a high forecast of 147 000 KRW.
Shareholder Return
Price
ST Pharm Co Ltd
Average Annual Return | 73.03% |
Standard Deviation of Annual Returns | 123.7% |
Max Drawdown | -58% |
Market Capitalization | 1.7T KRW |
Shares Outstanding | 18 933 900 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
ST Pharm Co., Ltd. develops and manufactures pharmaceutical products. The company is headquartered in Siheung, Gyeonggi-Do. The company went IPO on 2016-06-23. is a Korea-based company principally engaged in manufacture of pharmaceutical products. The firm's products mainly consist of generic active pharmaceutical ingredients (APIs), such as tipepidine hibenzate, doxifluridine, clopidogrel bisulfate, voriconazole and new medicine APIs, such as small molecule APIs. The firm distributes its products within domestic market and to overseas markets.
Contact
IPO
Employees
Officers
The intrinsic value of one ST Pharm Co Ltd stock under the Base Case scenario is 129 191.06 KRW.
Compared to the current market price of 91 200 KRW, ST Pharm Co Ltd is Undervalued by 29%.